|Trade names||Rifater, Trifazid, others|
|Defined daily dose||not established|
|AHFS/Drugs.com||FDA Professional Drug Information|
Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, is a medication used to treat tuberculosis. It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide. It is used either by itself or along with other antituberculosis medication. It is taken by mouth.
Side effects are those of the underlying medications. These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness. Severe side effects include liver problems. Use in those under the age of 15 may not be appropriate. It is unclear if use in pregnancy is safe for the baby.
Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994. It is on the World Health Organization's List of Essential Medicines. The wholesale cost in the developing world is about US$3.93 a month. In the United Kingdom a month of treatment costs the NHS about 39.51 pounds.
The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications. Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.
Society and culture
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 18 September 2020. CS1 maint: discouraged parameter (link)
- World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 143. hdl:10665/44053. ISBN 9789241547659.
- "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016. CS1 maint: discouraged parameter (link)
- "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016. CS1 maint: discouraged parameter (link)
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Rifampicin + Isoniazid + Pyrazinamide". International Drug Price Indicator Guide. Retrieved 8 December 2016. CS1 maint: discouraged parameter (link)
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 403. ISBN 9780857111562.
- Brown, Morris J.; Sharma, Pankaj; Bennett, Peter N. (30 July 2012). Clinical Pharmacology. Elsevier Health Sciences. p. 204. ISBN 978-0-7020-5113-5.